JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NCT04720976 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
NSCLC

Interventions

DRUG: JAB-3312
DRUG: Binimetinib
DRUG: Pembrolizumab
DRUG: Sotorasib
DRUG: Osimertinib

Sponsor

Allist Pharmaceuticals, Inc.

Collaborators

[object Object]